A reasonable proposition:

"Given the growth of withdrawals due to negative confirmatory trials and emerging evidence on the high spending associated with AA drugs, it is critical to balance early access against population-level exposure to cancer therapies with no benefit over standard of care."

https://jamanetwork.com/journals/jamaoncology/fullarticle/2801800?guestAccessKey=240ee0d5-8178-4853-ac08-67943bd5b8f5&utm_source=linkedin_company&utm_medium=social_jamaonc&utm_term=9000543678&utm_campaign=article_alert&linkId=202772565